Refine
Has Fulltext
- yes (82)
Is part of the Bibliography
- yes (82)
Year of publication
Document Type
- Journal article (59)
- Doctoral Thesis (22)
- Report (1)
Keywords
- platelet (9)
- platelets (9)
- ischemic stroke (7)
- LASP1 (6)
- atherosclerosis (6)
- Thrombozyt (5)
- megakaryocytes (5)
- thrombo-inflammation (5)
- Arteriosklerose (4)
- CXCR4 (4)
- platelet activation (4)
- Atherosclerosis (3)
- Atherosklerose (3)
- Cytoskeleton (3)
- Megakaryozyt (3)
- cytoskeleton (3)
- epigenetics (3)
- glycoprotein VI (3)
- inflammation (3)
- mouse (3)
- platelet aggregation (3)
- thrombin (3)
- thrombopoiesis (3)
- thrombosis (3)
- AAA (2)
- CML (2)
- COVID-19 (2)
- Caenorhabditis elegans (2)
- Herzinfarkt (2)
- Knochenmark (2)
- Makrophage (2)
- Phagozytose (2)
- Zellskelett (2)
- Zelltod (2)
- actin cytoskeleton (2)
- aortic arch (2)
- bone marrow (2)
- breast cancer (2)
- collagens (2)
- cytotoxic T cells (2)
- glycoprotein receptor Ib (2)
- hematology (2)
- ischemic penumbra (2)
- mice (2)
- middle cerebral artery occlusion (2)
- mouse models (2)
- platelet receptors (2)
- pulse wave velocity (2)
- signaling (2)
- stem cells (2)
- translational research (2)
- wall shear stress (2)
- 3D image analysis (1)
- 4D flow (1)
- 4D flow MRI (1)
- 7-Dehydrocholesterol (1)
- A20 (1)
- ADAM10 (1)
- AKT (1)
- AKT1 (1)
- AP-1 (1)
- Abszision (1)
- Actin (1)
- Actin-bindende Proteine (1)
- Adhesion and degranulation promoting adapter protein (1)
- Akt (1)
- Artery Models (1)
- Atherogenese (1)
- Autophagie (1)
- B cell (1)
- B cell maturation (1)
- B cell receptor (1)
- BCR‐ABL (1)
- Batf3 (1)
- Bericht (1)
- Biofabrication (1)
- Biomarker (1)
- CCR6 (1)
- CD147 (1)
- CD2AP (1)
- CD8\(^+\) T cells (1)
- CMR (1)
- CVD (1)
- Canis lupus familiaris (1)
- Cdc42 (1)
- Chemokine (1)
- Cholesterin (1)
- Cholesterol (1)
- Chronisch-myeloische Leukämie (1)
- Collaborative Research Center (1)
- Cyclophilin A (1)
- DHCR7 (1)
- Dendritische Zelle (1)
- Differential RNA-sequencing (1)
- Domäne <Biochemie> (1)
- Dünndarm (1)
- E2 conjugating enzyme (1)
- E3 ligating enzyme (1)
- EMMPRIN (1)
- ERK map kinease (1)
- ERK1/2 (1)
- Epigenetik (1)
- Experimental Biomedicine (1)
- Extracellular matrix proteins (1)
- Extrazelluläre Matrix (1)
- Ferroptose (1)
- Ferroptosis (1)
- GABP (1)
- GPVI (1)
- GSK-3β (1)
- Ganzkörperbestrahlung (1)
- Graft-versus-host disease (GvHD) (1)
- HIF-1α (1)
- Helicobacter pylori (1)
- Hemodynamics (1)
- Histologie (1)
- Hypoxie-induzierbarer Faktor (1)
- Hämodynamik (1)
- IgD (1)
- IgM (1)
- JAQ1 (1)
- KAT/HAT (1)
- Kardiovaskuläre Erkrankungen (1)
- Knochenmarktransplantation (1)
- LC3-associated phagocytosis (1)
- LC3-assoziierte Phagozytose (1)
- MGL (1)
- MRI (1)
- Macrophages (1)
- Mast cells (1)
- Megakaryocyte (1)
- Megakaryocytes (1)
- Monozyten (1)
- Myocardial infarction (1)
- Neutrophils (1)
- Optogenetik (1)
- Orai2 (1)
- PD-L1 (1)
- PWV (1)
- Platelet (1)
- Polkörper (1)
- Proteininteraktion (1)
- Proteinsynthese (1)
- RKIP (1)
- Rekrutierung (1)
- RhoA (1)
- RhoF (1)
- SARS-CoV-2 (1)
- SET7 (1)
- Sepsis (1)
- Septine (1)
- Single-cell RNA Sequencing (1)
- Snail1 stability (1)
- Sonderforschungsbereich Transregio 240 (1)
- Strumpellin (1)
- Syk (1)
- T cell (1)
- T-Lymphozyt (1)
- T-Lymphozyten (1)
- T-cell epitope (1)
- T-cells (1)
- Tet‐inducible system (1)
- Thrombopoiesis (1)
- Thrombozytenfunktion (1)
- Thrombozytopenie (1)
- Tissue Engineering (1)
- TspanC8 (1)
- Urothelkrebs (1)
- WASH complex (1)
- WSS (1)
- ZF1 degradation assay (1)
- ZIP (1)
- Zellteilung (1)
- acetylation (1)
- acetyltransferases (1)
- actin-binding proteins (1)
- actins (1)
- acute Respiratory Distress Syndrome (1)
- adaptor protein Swiprosin-1/EFhd2 (1)
- adipose tissue (1)
- algorithm (1)
- alpha-IIb beta-3 (1)
- angiotensin (1)
- animal models (1)
- arterial elasticity (1)
- basic (laboratory) research / science (1)
- bioenergetics (1)
- bioinformatics (1)
- bleding disorders other than hemophilia (1)
- blood (1)
- blood coagulation (1)
- blood flow (1)
- blood platelets (1)
- body weight (1)
- brain (1)
- c-Fos (1)
- cag pathogenicity island (1)
- campylobacter jejuni infection (1)
- cancer (1)
- cardiovascular MRI (1)
- cardiovascular disease (1)
- carotid arteries (1)
- cascade (1)
- cerebellum (1)
- cerebrovascular disorders (1)
- checkpoint inhibitors (1)
- chemokines (1)
- coagulation (1)
- coagulation and hemostasis (1)
- coatings (1)
- coffin-lowry-syndrome (1)
- complex (1)
- controllability (1)
- cyclase-associated protein (1)
- cyclase-associated protein 2 (1)
- deficiency (1)
- dendritic cells (1)
- dendritic growth (1)
- dentate gyrus (1)
- disaggregation (1)
- disease (1)
- dog (1)
- drug repurposing (1)
- early diagnosis (1)
- ectopic release (1)
- embryos (1)
- en bloc transfer (1)
- endosomal trafficking (1)
- endothelial cell (1)
- endothelial cells (1)
- enzyme regulation (1)
- epithelial cells (1)
- epitope prediction (1)
- evolution (1)
- extracellular matrix (1)
- factor XII (1)
- fibrin (1)
- filopodia (1)
- flow (1)
- flow dynamics (1)
- fluorescence microscopy (1)
- fostamatinib (1)
- genetic modification (1)
- glaucoma (1)
- glycoprotein Ib (1)
- glycoprotein Ibα (1)
- glycoprotein receptor Ibα (1)
- graft survival (1)
- granule cells (1)
- guidelines (1)
- haemostasis (1)
- heart (1)
- hemostasis and thrombosis (1)
- hemostasis, (1)
- hippocampus (1)
- histologic diversity (1)
- histology (1)
- histone acetylation (1)
- homeostasisIon channels (1)
- human (1)
- human hematopoiesis (1)
- hypothalamus (1)
- iPS cells (1)
- immune-informatics (1)
- immunoglobulin repertoire (1)
- immunoglobulin superfamily (1)
- immunotherapy (1)
- impedance aggregometry; WHOLE-BLOOD THROMBOELASTOMETRY; DEFINITION; DISEASE (1)
- in vitro and in vivo thrombus formation (1)
- infection (1)
- influenza (1)
- inherited macrothrombocytopenia (1)
- insulin (1)
- insulin resistance (1)
- integrin α2 (1)
- integrins (1)
- interaction (1)
- interactome (1)
- interspecies comparison (1)
- intracranial bleeding (1)
- islet transplantation (1)
- laboratory animals (1)
- large animal models (1)
- leukemia (1)
- light sheet fluorescence microscopy (1)
- lncRNAs (1)
- long-term potentation (1)
- lung cancer (1)
- lung injury (1)
- lymphocyte differentiation (1)
- magnetic resonance imaging (1)
- mapping (1)
- matrix metalloproteinases (1)
- megakaryocyte (1)
- metalloproteinase (1)
- miRNA expression (1)
- miRNAs (1)
- microscopy (1)
- midbody remnant (1)
- molecular biology (1)
- monocyte (1)
- monocyte-platelet aggregates (1)
- myeloablation (1)
- nephrocyte (1)
- network (1)
- neurite outgrowth (1)
- neurology (1)
- neuronal dendrites (1)
- neuronal differentiation (1)
- neurons (1)
- neurotrophic factor (1)
- neurotrophic factors (1)
- nilotinib (1)
- non-invasive biomarkers (1)
- nucleus (1)
- occlusion (1)
- optical clearing (1)
- optogenetics (1)
- organoid (1)
- pathway analysis (1)
- phagosome maturation (1)
- phosphatidic acid (1)
- phospholipase D (1)
- phosphorylation (1)
- pig (1)
- pigmentation (1)
- plaque (1)
- plaque characteristics (1)
- platelet biogenesis (1)
- platelet degranulation (1)
- platelet disorders (1)
- platelet inhibition (1)
- pneumonia (1)
- point of care testing (1)
- polymers (1)
- popliteal aneurysm (1)
- positive selection (1)
- precursor cells (1)
- proplatelets (1)
- protein RSK2 (1)
- proteome (1)
- quantification (1)
- radial (1)
- recombinant tissue-type plasminogen activator (1)
- recruitment (1)
- regulatory circuit downstream (1)
- research infrastructure (1)
- retroviral vectors (1)
- second messenger (1)
- self-navigation (1)
- sequential addition (1)
- serotonin (1)
- shedding (1)
- signaling network (1)
- single cell RNA sequencing (1)
- slit membrane (1)
- spatiotemporal thrombus (1)
- stent implantation (1)
- stroke (1)
- structure (1)
- tMCAO (1)
- tetraspanin (1)
- therapy (1)
- thrombocyte (1)
- thrombocytopenia (1)
- thromboelastometry (1)
- thrombus (1)
- transcriptional regulation (1)
- transcriptome (1)
- transendothelial migration (1)
- transient middle cerebral artery (1)
- transient middle cerebral artery occlusion (1)
- tumor microenvironment (1)
- tyrosine kinase (1)
- ubiquitin (1)
- ultrahigh-field MRI (1)
- vascular structure (1)
- zinc (1)
Institute
- Institut für Experimentelle Biomedizin (82) (remove)
Sonstige beteiligte Institutionen
Studies on the role of cytoskeletal-regulatory and -crosslinking proteins in platelet function
(2023)
Cytoskeletal reorganization in platelets is highly regulated and important for proper platelet function during activation and aggregation at sites of vascular injury. In this thesis, the role of three different cytoskeletal-regulatory and -crosslinking proteins was studied in platelet physiology using megakaryocyte- and platelet-specific knockout mice. The generation of branched actin filaments is regulated by nucleation promoting factors (NPF) and the Arp2/3 complex.
(1.) The WAVE complex is a NPF, which upregulates the Arp2/3 complex activity at the plasma membrane. As shown in this thesis, the loss of the WAVE complex subunit Cyfip1 in mice did not alter platelet production and had only a minor impact on platelet activation. However, Cyfip1 played an essential role for branching of actin filaments and consequently for lamellipodia formation in vitro. The importance of lamellipodia for thrombus formation and stability has been controversially discussed. Cyfip1-deficient platelets were able to form a stable thrombus ex vivo and in vivo and a hemostatic plug comparable to controls. Moreover, Cyfip1-deficient mice maintained vascular integrity at the site of inflammation. These data show that platelet lamellipodia formation is not required for hemostatic function and pathophysiological thrombus formation.
(2.) The WASH complex is another NPF, which mediates actin filament polymerization on endosomal vesicles via the Arp2/3 complex. Loss of the WASH complex subunit Strumpellin led to a decreased protein abundance of the WASH protein and to a 20% reduction in integrin αIIbβ3 surface expression on platelets and megakaryocytes, whereas the expression of other surface receptors as well as the platelet count, size, ex vivo thrombus formation and bleeding time remained unaltered. These data point to a distinct role of Strumpellin in maintaining integrin αIIbβ3 expression and provide new insights into regulatory mechanisms of platelet integrins.
(3.) MACF1 has been described as a cytoskeletal crosslinker of microtubules and F-actin. However, MACF1-deficient mice displayed no alterations in platelet production, activation, thrombus formation and hemostatic function. Further, no compensatory up- or downregulation of other proteins could be found that contain an F-actin- and a microtubule-binding domain. These data indicate that MACF1 is dispensable for platelet biogenesis, activation and thrombus formation. Nevertheless, functional redundancy among different proteins mediating the cytoskeletal crosstalk may exist.
T cell exhaustion is a hallmark of cancer and persistent infections, marked by inhibitory receptor upregulation, diminished cytokine secretion, and impaired cytolytic activity. Terminally exhausted T cells are steadily replenished by a precursor population (Tpex), but the metabolic principles governing Tpex maintenance and the regulatory circuits that control their exhaustion remain incompletely understood. Using a combination of gene-deficient mice, single-cell transcriptomics, and metabolomic analyses, we show that mitochondrial insufficiency is a cell-intrinsic trigger that initiates the functional exhaustion of T cells. At the molecular level, we find that mitochondrial dysfunction causes redox stress, which inhibits the proteasomal degradation of hypoxia-inducible factor 1α (HIF-1α) and promotes the transcriptional and metabolic reprogramming of Tpex cells into terminally exhausted T cells. Our findings also bear clinical significance, as metabolic engineering of chimeric antigen receptor (CAR) T cells is a promising strategy to enhance the stemness and functionality of Tpex cells for cancer immunotherapy.
Ultra-high field cardiac MRI in large animals and humans for translational cardiovascular research
(2023)
A key step in translational cardiovascular research is the use of large animal models to better understand normal and abnormal physiology, to test drugs or interventions, or to perform studies which would be considered unethical in human subjects. Ultrahigh field magnetic resonance imaging (UHF-MRI) at 7 T field strength is becoming increasingly available for imaging of the heart and, when compared to clinically established field strengths, promises better image quality and image information content, more precise functional analysis, potentially new image contrasts, and as all in-vivo imaging techniques, a reduction of the number of animals per study because of the possibility to scan every animal repeatedly. We present here a solution to the dual use problem of whole-body UHF-MRI systems, which are typically installed in clinical environments, to both UHF-MRI in large animals and humans. Moreover, we provide evidence that in such a research infrastructure UHF-MRI, and ideally combined with a standard small-bore UHF-MRI system, can contribute to a variety of spatial scales in translational cardiovascular research: from cardiac organoids, Zebra fish and rodent hearts to large animal models such as pigs and humans. We present pilot data from serial CINE, late gadolinium enhancement, and susceptibility weighted UHF-MRI in a myocardial infarction model over eight weeks. In 14 pigs which were delivered from a breeding facility in a national SARS-CoV-2 hotspot, we found no infection in the incoming pigs. Human scanning using CINE and phase contrast flow measurements provided good image quality of the left and right ventricle. Agreement of functional analysis between CINE and phase contrast MRI was excellent. MRI in arrested hearts or excised vascular tissue for MRI-based histologic imaging, structural imaging of myofiber and vascular smooth muscle cell architecture using high-resolution diffusion tensor imaging, and UHF-MRI for monitoring free radicals as a surrogate for MRI of reactive oxygen species in studies of oxidative stress are demonstrated. We conclude that UHF-MRI has the potential to become an important precision imaging modality in translational cardiovascular research.
B cell maturation and immunoglobulin (Ig) repertoire selection are governed by expression of a functional B cell receptor (BCR). Naïve B cells co-express their BCR as IgM and IgD isotype. However, the role of the additionally expressed IgD on naïve B cells is not known. Here we assessed the impact of IgD on naïve B cell maturation and Ig repertoire selection in 8 individuals from 3 different families with heterozygous loss-of-function or loss-of expression mutations in IGHD. Although naïve B cells from these individuals expressed IgM on their surface, the IGHD variant in heterozygous state entailed a chimeric situation by allelic exclusion with almost half of the naïve B cell population lacking surface IgD expression. Flow cytometric analyses revealed a distinct phenotype of IgD-negative naïve B cells with decreased expression of CD19, CD20 and CD21 as well as lower BAFF-R and integrin-β7 expression. IgD-negative B cells were less responsive in vitro after engaging the IgM-BCR, TLR7/9 or CD40 pathway. Additionally, a selective disadvantage of IgD-negative B cells within the T2 transitional and mature naïve B cell compartment as well as reduced frequencies of IgMlo/- B cells within the mature naïve B cell compartment lacking IgD were evident. RNA-Ig-seq of bulk sorted B cell populations showed an altered selection of distinct VH segments in the IgD-negative mature naïve B cell population. We conclude that IgD expression on human naïve B cells is redundant for generation of naïve B cells in general, but further shapes the naive B cell compartment starting from T2 transitional B cells. Our observations suggest an unexpected role of IgD expression to be critical for selection of distinct Ig VH segments into the pre-immune Ig repertoire and for the survival of IgMlo/- naïve B cells known to be enriched in poly-/autoreactive B cell clones.
Zinc (Zn2+) is considered as important mediator of immune cell function, thrombosis and haemostasis. However, our understanding of the transport mechanisms that regulate Zn2+ homeostasis in platelets is limited. Zn2+ transporters, ZIPs and ZnTs, are widely expressed in eukaryotic cells. Using mice globally lacking ZIP1 and ZIP3 (ZIP1/3 DKO), our aim was to explore the potential role of these Zn2+ transporters in maintaining platelet Zn2+ homeostasis and in the regulation of platelet function. While ICP-MS measurements indicated unaltered overall Zn2+ concentrations in platelets of ZIP1/3 DKO mice, we observed a significantly increased content of FluoZin3-stainable free Zn2+, which, however, appears to be released less efficiently upon thrombin-stimulated platelet activation. On the functional level, ZIP1/3 DKO platelets exhibited a hyperactive response towards threshold concentrations of G protein-coupled receptor (GPCR) agonists, while immunoreceptor tyrosine-based activation motif (ITAM)-coupled receptor agonist signalling was unaffected. This resulted in enhanced platelet aggregation towards thrombin, bigger thrombus volume under flow ex vivo and faster in vivo thrombus formation in ZIP1/3 DKO mice. Molecularly, augmented GPCR responses were accompanied by enhanced Ca2+ and PKC, CamKII and ERK1/2 signalling. The current study thereby identifies ZIP1 and ZIP3 as important regulators for the maintenance of platelet Zn2+ homeostasis and function.
In tumor therapy anti-angiogenic approaches have the potential to increase the efficacy of a wide variety of subsequently or co-administered agents, possibly by improving or normalizing the defective tumor vasculature. Successful implementation of the concept of vascular normalization under anti-angiogenic therapy, however, mandates a detailed understanding of key characteristics and a respective scoring metric that defines an improved vasculature and thus a successful attempt. Here, we show that beyond commonly used parameters such as vessel patency and maturation, anti-angiogenic approaches largely benefit if the complex vascular network with its vessel interconnections is both qualitatively and quantitatively assessed. To gain such deeper insight the organization of vascular networks, we introduce a multi-parametric evaluation of high-resolution angiographic images based on light-sheet fluorescence microscopy images of tumors. We first could pinpoint key correlations between vessel length, straightness and diameter to describe the regular, functional and organized structure observed under physiological conditions. We found that vascular networks from experimental tumors diverted from those in healthy organs, demonstrating the dysfunctionality of the tumor vasculature not only on the level of the individual vessel but also in terms of inadequate organization into larger structures. These parameters proofed effective in scoring the degree of disorganization in different tumor entities, and more importantly in grading a potential reversal under treatment with therapeutic agents. The presented vascular network analysis will support vascular normalization assessment and future optimization of anti-angiogenic therapy.
Introduction
Pro-thrombotic events are one of the prevalent causes of intensive care unit (ICU) admissions among COVID-19 patients, although the signaling events in the stimulated platelets are still unclear.
Methods
We conducted a comparative analysis of platelet transcriptome data from healthy donors, ICU, and non-ICU COVID-19 patients to elucidate these mechanisms. To surpass previous analyses, we constructed models of involved networks and control cascades by integrating a global human signaling network with transcriptome data. We investigated the control of platelet hyperactivation and the specific proteins involved.
Results
Our study revealed that control of the platelet network in ICU patients is significantly higher than in non-ICU patients. Non-ICU patients require control over fewer proteins for managing platelet hyperactivity compared to ICU patients. Identification of indispensable proteins highlighted key subnetworks, that are targetable for system control in COVID-19-related platelet hyperactivity. We scrutinized FDA-approved drugs targeting indispensable proteins and identified fostamatinib as a potent candidate for preventing thrombosis in COVID-19 patients.
Discussion
Our findings shed light on how SARS-CoV-2 efficiently affects host platelets by targeting indispensable and critical proteins involved in the control of platelet activity. We evaluated several drugs for specific control of platelet hyperactivity in ICU patients suffering from platelet hyperactivation. The focus of our approach is repurposing existing drugs for optimal control over the signaling network responsible for platelet hyperactivity in COVID-19 patients. Our study offers specific pharmacological recommendations, with drug prioritization tailored to the distinct network states observed in each patient condition. Interactive networks and detailed results can be accessed at https://fostamatinib.bioinfo-wuerz.eu/.
Cyclophilin a is not acetylated at lysine-82 and lysine-125 in resting and stimulated platelets
(2022)
Cyclophilin A (CyPA) is widely expressed by all prokaryotic and eukaryotic cells. Upon activation, CyPA can be released into the extracellular space to engage in a variety of functions, such as interaction with the CD147 receptor, that contribute to the pathogenesis of cardiovascular diseases. CyPA was recently found to undergo acetylation at K82 and K125, two lysine residues conserved in most species, and these modifications are required for secretion of CyPA in response to cell activation in vascular smooth muscle cells. Herein we addressed whether acetylation at these sites is also required for the release of CyPA from platelets based on the potential for local delivery of CyPA that may exacerbate cardiovascular disease events. Western blot analyses confirmed the presence of CyPA in human and mouse platelets. Thrombin stimulation resulted in CyPA release from platelets; however, no acetylation was observed—neither in cell lysates nor in supernatants of both untreated and activated platelets, nor after immunoprecipitation of CyPA from platelets. Shotgun proteomics detected two CyPA peptide precursors in the recombinant protein, acetylated at K28, but again, no acetylation was found in CyPA derived from resting or stimulated platelets. Our findings suggest that acetylation of CyPA is not a major protein modification in platelets and that CyPA acetylation is not required for its secretion from platelets.
Platelets play an essential role in haemostasis. Through granule secretion of second wave mediators and aggregation, they secure vascular integrity. Due to incorrect activation, platelet aggregation and subsequent thrombus formation can cause blood vessel occlusion, leading to ischemia. Patients with defects in platelet production have a low platelet count (thrombocytopenia), which can cause an increased bleeding risk. In vitro platelet generation is still in its development phase. So far, no convincing results have been obtained. For this reason, the health care system still depends on blood donors. Platelets are produced by bone marrow megakaryocytes (MKs), which extend long cytoplasmic protrusions, designated proplatelets, into sinusoidal blood vessels. Due to shear forces, platelets are then released into the bloodstream. The molecular mechanisms underlying platelet production are still not fully understood. However, a more detailed insight of this biological process is necessary to improve the in vitro generation of platelets and to optimise treatment regimens of patients.
Optogenetics is defined as “light-modulation of cellular activity or of animal behaviour by gene transfer of photo-sensitive proteins”. Optogenetics has had a big impact on neuroscience over the last decade. The use of channelrhodopsin 2 (ChR2), a light-sensitive cation channel, made it possible to stimulate neurons precisely and minimally invasive for the first time. Recent developments in the field of optogenetics intend to address a broader scope of cellular and molecular biology.
The aim of this thesis is to establish optogenetics in the field of MK research in order to precisely control and manipulate MK differentiation. An existing “optogenetic toolbox“ was used, which made it possible to light-modulate the cellular concentration of specific signalling molecules and ion conductance in MKs. Expression of the bacterial photoactivated adenylyl cyclase (bPAC) resulted in a significant increase in cAMP concentration after 5 minutes of illumination. Similarly, intracellular cGMP concentrations in MKs expressing photoactivated guanylyl cyclase (BeCyclop) were elevated. Furthermore, proplatelet formation of MKs expressing the light-sensitive ion channels ChR2 and anion channelrhodopsin (ACR) was altered in a light-dependent manner. These results show that MK physiology can be modified by optogenetic approaches. This might help shed new light on the underlying mechanisms of thrombopoiesis.
Understanding the pathways involved in the formation and stability of the core and shell regions of a platelet-rich arterial thrombus may result in new ways to treat arterial thrombosis. The distinguishing feature between these two regions is the absence of fibrin in the shell which indicates that in vitro flow-based assays over thrombogenic surfaces, in the absence of coagulation, can be used to resemble this region. In this study, we have investigated the contribution of Syk tyrosine kinase in the stability of platelet aggregates (or thrombi) formed on collagen or atherosclerotic plaque homogenate at arterial shear (1000 s\(^{−1}\)). We show that post-perfusion of the Syk inhibitor PRT-060318 over preformed thrombi on both surfaces enhances thrombus breakdown and platelet detachment. The resulting loss of thrombus stability led to a reduction in thrombus contractile score which could be detected as early as 3 min after perfusion of the Syk inhibitor. A similar loss of thrombus stability was observed with ticagrelor and indomethacin, inhibitors of platelet adenosine diphosphate (ADP) receptor and thromboxane A\(_2\) (TxA\(_2\)), respectively, and in the presence of the Src inhibitor, dasatinib. In contrast, the Btk inhibitor, ibrutinib, causes only a minor decrease in thrombus contractile score. Weak thrombus breakdown is also seen with the blocking GPVI nanobody, Nb21, which indicates, at best, a minor contribution of collagen to the stability of the platelet aggregate. These results show that Syk regulates thrombus stability in the absence of fibrin in human platelets under flow and provide evidence that this involves pathways additional to activation of GPVI by collagen.